Comparison Study of Two Supraglottic Devices Used for Patients Under General Anesthesia
Recruitment status was Recruiting
|First Received Date ICMJE||October 21, 2009|
|Last Updated Date||October 22, 2009|
|Start Date ICMJE||September 2009|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures ICMJE
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT01001078 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Comparison Study of Two Supraglottic Devices Used for Patients Under General Anesthesia|
|Official Title ICMJE||Prospective Randomized Trial Comparing the Performance of Two Supraglottic Airway Management Devices: I-Gel and Supreme LMA|
This study will compare two supraglottic airway devices currently on the market. Supraglottic airway devices are used during general anesthesia to provide a patent airway. They are inserted blindly into the mouth once the patient has lost consciousness and they cover the laryngeal inlet. The I-Gel and the Supreme LMA are the two devices to be compared. The I-Gel has no inflatable cuff, which makes it different from all other supraglottic airway devices currently in use. The Supreme shares some characteristics of the other LMA devices, but it is disposable. Our main goal will be to compare the airway leak pressure and the peak airway pressure of each devices. We will also measure the time needed for insertion, number of attempts needed to secure the airway and side effects related to the airway (cough, dysphagia, trauma, hoarseness of voice, sore throat).
First of all, we will record the following demographic variables: age, sex, height, weight, BMI, surgery planned, ASA status, dental state (good, bad, edentulous), tobacco use (none, ceased, active) and packs year, Mallampati score, thyromental distance and whether or not there is trauma on the tongue, teeth or lips prior to surgery.
Induction of anesthesia will be standardized with Fentanyl 1-3 mcg/kg and Propofol 1-3,5 mg/Kg. The use of myorelaxant will be mandatory, but either succinylcholine or rocuronium will be used as long as complete disparition of T1 is observed before attempting supraglottic airway insertion.
Prior to insertion, ease of ventilation (yes/no) will be noted.
The two airway devices will be used according to manufacturers instructions. The sizes of the devices will be chosen according to weight:
I-Gel: 50-90 kG: #4 and 90 Kg and up: #5 LMA Supreme: 50-70 Kg: #4 and 70-100 Kg: #5.
Patients will be randomized in either I-Gel or LMA Supreme group. Two insertions with the same device will be allowed before a crossover to the other device. If the third attempt fails, a standard endotracheal tube will be put in the trachea and blood in the oral cavity will be sought. After each failed attempt (no thoracic expansion, no CO2 square wave or leak at standardized volume. Blood on the devices will also be recorded.
Since the LMA Supreme has a cuff, we will inflate it to 25 mL and then by intervals of 5 mL of air (max 45 mL) we will inflate it at a volume where no audible leak is heard at a standardized ventilation scheme of volume controlled 8mL/kg X 10 breaths per minute.
Once fixed with tape, we will measure peak and mean airway pressure for three breaths after 30 seconds of volume controlled breathing. Then the fresh gas flow will be fixed at 3 L/min of 50-50 air-oxygen blend and the Adjustable Pressure Limiting valve will be closed. We will look either for a plateau pressure at which a leak equal to the fresh gas flow or a pressure of 40 cm H2O.
We will sought adverse effect like bronchospasm, cough, regurgitation, desaturation, aspiration and deglutition movement.
Ease of insertion will be score on a scale of 1 to 4. 1 being very easy and 4 being very hard.
Endoscopic evaluation will take place afterwards. First in the ventilation tube. Scoring for laryngeal view:
Downfolding of the epiglottis will be sought.
Then we will go through the oesophageal port and see if the oesophageal mucosa il visible.
During surgery, we will check if airway manipulation and/or withdrawal was necessary and why.
If traces of blood on the devices are present at the end of the intervention it will be noted.
Two interviews will take place one at the post anesthesia care unit and another the following day by phone if the patient was having ambulatory surgery. Sore throat, cough, dysphagia and dysphonia will be asked to be graded: absent, mild, moderate or severe.
Pulse and arterial pressure with the operating room's sphygmomanometer and saturometer will be written before induction, after induction before insertion and at 1 and 2 minutes post insertion.
|Study Type ICMJE||Observational|
|Study Design ICMJE||Observational Model: Case-Only
Time Perspective: Prospective
|Target Follow-Up Duration||Not Provided|
|Sampling Method||Probability Sample|
Any subject planned to have general anesthesia for elective surgery
|Condition ICMJE||Patent Airway|
|Intervention ICMJE||Device: Supraglottic airway device insertion
In the I-Gel group, 2 attempts to secure the airway will be tried. If they both fail, there will be a crossover with a Supreme LMA. Peak and mean airway pressure will be measured once the device is fixed with tape to the patient. Leak pressure will be measured as well. It will be done while closing the Adjustable Pressure Limiting valve and putting the fresh gas flow at 3 L/min. We will be looking at the manometer to see either a plateau (that would be a leak equal to the fresh gas flow) or the maximum allowed pressure 40 cm H2O.
In the LMA Supreme group, the same interventions will be done as in the I-Gel group. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Leak pressure will also be measure at 45 mL. Once the leak test is done, the cuff will be deflated to initial volume necessary to avoid audible leaks.
|Study Group/Cohort (s)||
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Recruiting|
|Estimated Enrollment ICMJE||100|
|Completion Date||Not Provided|
|Primary Completion Date||Not Provided|
|Eligibility Criteria ICMJE||
|Ages||18 Years and older|
|Accepts Healthy Volunteers||Yes|
|Location Countries ICMJE||Canada|
|NCT Number ICMJE||NCT01001078|
|Other Study ID Numbers ICMJE||HMR-Anesth-Joly|
|Has Data Monitoring Committee||No|
|Responsible Party||Pierre Drolet, Hôpital Maisonneuve-Rosemont|
|Study Sponsor ICMJE||Maisonneuve-Rosemont Hospital|
|Collaborators ICMJE||Not Provided|
|Information Provided By||Maisonneuve-Rosemont Hospital|
|Verification Date||October 2009|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP